We propose that pre-treatment levels of LAG-3+ and CD8+ cells in tumor tissue should be explored further to help identify HCC patients likely to benefit from immunotherapy using IHC-based techniques that are readily accessible during routine clinical care. The gene discussed is CD8A; the disease is neoplasm.